核医学のアジア太平洋市場2021年-2028年:種類別(診断、治療、生化学研究)、モダリティ別、用途別、エンドユーザー別

◆英語タイトル:Asia-Pacific Nuclear Medicine Market by Type (Diagnostics, Therapeutics, and Biochemistry Research), Modality (SPECT, PET, Beta emitters, Alpha Emitters, Brachytherapy, and Others), Application (Oncology, Cardiology, Thyroid, Neurology, ad Others) and End User (Hospitals & Diagnostic Centers and Research Institutes): Regional Opportunity Analysis and Industry Forecast, 2021–2028
◆商品コード:AMR21JU100
◆発行会社(リサーチ会社):Allied Market Research
◆発行日:2021年5月27日
◆ページ数:142
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:アジア太平洋
◆販売価格オプション(消費税別)
Single UserUSD3,809 ⇒換算¥418,990見積依頼/購入/質問フォーム
5 UserUSD4,096 ⇒換算¥450,560見積依頼/購入/質問フォーム
Enterprise UserUSD5,712 ⇒換算¥628,320見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はAllied Market Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Allied Market Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査資料では、核医学のアジア太平洋市場について調査し、イントロダクション、エグゼクティブサマリー、市場状況、種類別(診断、治療、生化学研究)分析、モダリティ別(SPECT、PET、ベータエミッター、アルファエミッター、小線源治療)分析、用途別(腫瘍、心臓病、甲状腺、神経、その他)分析、エンドユーザー別(病院・診断センター、研究機関)分析、地域別分析、企業情報などを掲載しています。
・イントロダクション
・エグゼクティブサマリー
・市場状況
・核医学のアジア太平洋市場規模:種類別(診断、治療、生化学研究)
・核医学のアジア太平洋市場規模:モダリティ別(SPECT、PET、ベータエミッター、アルファエミッター、小線源治療)
・核医学のアジア太平洋市場規模:用途別(腫瘍、心臓病、甲状腺、神経、その他)
・核医学のアジア太平洋市場規模:エンドユーザー別(病院・診断センター、研究機関)
・核医学のアジア太平洋市場規模:地域別
・企業情報
【レポートの概要】

The Asia-Pacific nuclear medicine market was valued at $4,116.43 million in 2020, and is projected to reach $8,957.89 million by 2028, registering a CAGR of 10.4% from 2021 to 2028.
Radiopharmaceuticals are pharmaceutical formulations comprise radioactive isotopes that are used in diagnosis and therapeutics. They are simple and small substances that contain a radioactive substance used in the treatment of cancer and cardiac & neurological disorders. Moreover, nuclear medicines of modality, SPECT and PET work as a convenient and safer alternative for patients as compared to X-Rays and other external radiation imaging devices. Applications such as lymphoma and bone metastasis use radiopharmaceuticals, also known as nuclear medicines. F-18, Tc-99, Ga-67, and I-123 are some of the nuclear medicines used in diagnostic procedures, while I-131, Ir192, Y-90, I-125, Lu-177, and Ra-223 are used in therapeutics procedure. More convenient therapeutic radiopharmaceuticals for oncology and cancer treatment replace the conventional chemotherapy methods to open up new avenues in the radiopharmaceuticals market.

The market is currently in its growth stage driven by increase in the number of cancer cases in the Asia-Pacific region and the surge awareness about nuclear medicine. Convenience of treatment with minimally invasive techniques attracts more patients toward the radiopharmaceuticals mode of treatment as compared to chemotherapy. The factors that drive the radiopharmaceuticals industry include increase in incidence of cardiac patients and adoption of clear imaging technique, with the help of diagnostic equipment such as PET and SPECT. The factors that hinder the growth of the market include supply shortages, logistical difficulties, and limited number of trained medical personnel.

The nuclear medicine market is categorized into type, modality, application, and end-user. On the basis of type, the market is segmented into diagnostics, therapeutics, and biochemistry research. The diagnostics segment led the market in 2020, and is anticipated to continue this trend during the forecast period, owing to the surge in prevalence of cancer that require early diagnosis for appropriate treatment could be provided in the Asia-Pacific region. Furthermore, rise in incidence of cardiac patients and clear imaging technique with the help of diagnostic equipment such as PET and SPECT is projected to help the diagnostics segment gain traction.

By modality, the Asia-Pacific nuclear medicine market is segregated into SPECT, PET, beta emitters, alpha emitters, brachytherapy, and others. The SPECT segment is expected to witness extensive market growth during the forecast period, owing to advantages of getting multiple 2-D and 3-D images, by performing SPECT imaging technique with the help of gamma camera aids in better access for the physicians to visualize the targeted area. Increase in the demand for the diagnosis of conditions such as cancer, cardiac, and neurology is expected to drive the growth of the industry during the forecast period.

By application, the Asia-Pacific nuclear medicine market is segregated into oncology, cardiology, thyroid, neurology and others. The oncology segment is expected to witness substantial market growth during the forecast period, owing to increase in cases of cancers and advancement of radio-therapeutics which has expedited the treatment process of cancerous tumors. However, thyroid segment is anticipated to gain highest CAGR, due to the growth in the number patient population in the coming years.

By end user, the Asia-Pacific nuclear medicine market is segregated into hospitals & diagnostics centers and research institutes. The hospitals & diagnostic centers segment is expected to witness significant market growth during the forecast period, owing to the surge in preference toward hospitals & diagnostic centers.

By country, China is expected to register the highest revenue share during the forecast period pertaining to the higher targeted population base, surge in awareness regarding early diagnosis and therapeutics of cancer and cardiac ailments, and rise in disposable income. However, India is anticipated to gain fastest CAGR, owing to the surge in the patient population in the country.

Competitive rivalry in the Asia-Pacific nuclear medicine market was observed at high level as major players have focused on the adoption of growth strategies such as product launches, mergers & acquisitions (M&As), and partnerships & collaborations to attain strong position in the competitive market. Key players operating in the Asia-Pacific nuclear medicine market include Bracco S.P.A. (Bracco Imaging S.P.A.), Bwx Technologies, Inc. (Nordion, Inc.), Cardinal Health, Inc., Danaher Corporation (GE Healthcare), FUJIFILM Toyama Chemical Co., Ltd. (FUJIFILM Holdings Corporation), Ion Beam Applications (Ion Beam Applications, SA), Lantheus Holdings, Inc. (Lantheus Medical Imaging, Inc.), Novartis AG (Advanced Accelerator Applications S.A.), Otsuka Holdings Co., Ltd. (ABX advanced biochemical compounds GmbH), and Siemens Healthcare GmbH.

KEY BENEFITS FOR STAKEHOLDERS
• The study provides an in-depth analysis of the Asia-Pacific nuclear medicine market size along with the current trends and future estimations to elucidate the imminent investment pockets
• It offers market analysis from 2021 to 2028, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market
• A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the Asia-Pacific nuclear medicine market growth

KEY MARKET SEGMENTS
By Type
• Diagnostics
• Therapeutics
• Biochemistry Research

By Modality
• SPECT
• PET
• Beta Emitters
• Alpha Emitters
• Brachytherapy
• Others

By Application
• Oncology
• Cardiology
• Thyroid
• Neurology
• Others

By End User
• Hospitals & Diagnostics Centers
• Research Institutes

By Country
• Asia-Pacific
o Japan
o China
o India
o South Korea
o Australia
o Rest of Asia-Pacific

List of key players profiled in the report
• Bracco S.P.A. (Bracco Imaging S.P.A.)
• Bwx Technologies, Inc. (Nordion, Inc.)
• Cardinal Health, Inc.
• Danaher Corporation (GE Healthcare)
• FUJIFILM Toyama Chemical Co., Ltd. (FUJIFILM Holdings Corporation)
• Ion Beam Applications (Ion Beam Applications, SA)
• Lantheus Holdings, Inc. (Lantheus Medical Imaging, Inc.)
• Novartis AG (Advanced Accelerator Applications S.A.)
• Otsuka Holdings Co., Ltd. (ABX advanced biochemical compounds GmbH)
• Siemens Healthcare GmbH

【レポートの目次】

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key Benefits for Stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Porter’s five force analysis
3.4.Top player positioning, 2020
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Increase in incidence and prevalence of target conditions
3.5.1.2.Alpha Radioimmunotherapy-Based Targeted Cancer Treatment
3.5.1.3.Surge in adoption of SPECT and PET scans
3.5.1.4.Developments in imaging technologies using radiopharmaceuticals

3.5.2.Restraint

3.5.2.1.Supply volatility, logistical challenges and stringent regulatory policies
3.5.2.2.Short half life of radiopharmaceuticals
3.5.2.3.Competition from conventional alternative diagnostic procedures

3.5.3.Opportunities

3.5.3.1.Use of radiopharmaceuticals in neurological applications

3.5.4.Impact analysis

3.6.COVID-19 Impact Analysis on Asia-Pacific nuclear medicines Market

CHAPTER 4:ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY TYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.Diagnostics

4.2.1.Key market trends and opportunities
4.2.2.Market size and forecast

4.3.Therapeutics

4.3.1.Key market trends and opportunities
4.3.2.Market size and forecast

4.4.Biochemistry Research

4.4.1.Key market trends and opportunities
4.4.2.Market size and forecast

CHAPTER 5:ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY MODALITY

5.1.Overview

5.1.1.Market size and forecast

5.2.SPECT

5.2.1.Market size and forecast

5.3.PET

5.3.1.Market size and forecast

5.4.Beta emitters’

5.4.1.Market size and forecast

5.5.Alpha emitters

5.5.1.Market size and forecast

5.6.Brachytherapy

5.6.1.Market size and forecast

5.7.Others

5.7.1.Market size and forecast

CHAPTER 6:ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY APPLICATION

6.1.Overview

6.1.1.Key market trends and opportunities
6.1.2.Market size and forecast

6.2.Oncology

6.2.1.Market size and forecast

6.3.Cardiology

6.3.1.Market size and forecast

6.4.Thyroid

6.4.1.Market size and forecast

6.5.Neurology

6.5.1.Market size and forecast

6.6.Others

6.6.1.Market size and forecast

CHAPTER 7:ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY END USER

7.1.Overview

7.1.1.Market size and forecast

7.2.Hospitals and Diagnostic Centers

7.2.1.Market size and forecast

7.3.Research Institutes

7.3.1.Market size and forecast

CHAPTER 8:ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY REGION

8.1.Overview
8.2.Asia-Pacific

8.2.1.Key market trends, growth factors, and opportunities
8.2.2.Market size and forecast, by country

8.2.2.1.Japan

8.2.2.1.1.Asia-Pacific nuclear medicine market, for Japan, by type
8.2.2.1.2.Asia-Pacific nuclear medicine market, for Japan, by modality
8.2.2.1.3.Asia-Pacific nuclear medicine market, for Japan, by application
8.2.2.1.4.Asia-Pacific nuclear medicine market, for Japan, by end user

8.2.2.2.China

8.2.2.2.1.Asia-Pacific nuclear medicine market, for China, by type
8.2.2.2.2.Asia-Pacific nuclear medicine market, for China, by modality
8.2.2.2.3.Asia-Pacific nuclear medicine market, for China, by application
8.2.2.2.4.Asia-Pacific nuclear medicine market, for China, by end user

8.2.2.3.India

8.2.2.3.1.Asia-Pacific nuclear medicine market, for India, by type
8.2.2.3.2.Asia-Pacific nuclear medicine market, for India, by modality
8.2.2.3.3.Asia-Pacific nuclear medicine market, for India, by application
8.2.2.3.4.Asia-Pacific nuclear medicine market, for India, by end user

8.2.2.4.South Korea

8.2.2.4.1.Asia-Pacific nuclear medicine market, for South Korea, by type
8.2.2.4.2.Asia-Pacific nuclear medicine market, for South Korea, by modality
8.2.2.4.3.Asia-Pacific nuclear medicine market, for South Korea, by application
8.2.2.4.4.Asia-Pacific nuclear medicine market, for South Korea, by end user

8.2.2.5.Australia

8.2.2.5.1.Asia-Pacific nuclear medicine market, for Australia, by type
8.2.2.5.2.Asia-Pacific nuclear medicine market, for Australia, by modality
8.2.2.5.3.Asia-Pacific nuclear medicine market, for Australia, by application
8.2.2.5.4.Asia-Pacific nuclear medicine market, for Australia, by end user

8.2.2.6.Rest of Asia-Pacific

8.2.2.6.1.Asia-Pacific nuclear medicine market, for Rest of Asia-Pacific, by type
8.2.2.6.2.Asia-Pacific nuclear medicine market, for Rest of Asia-Pacific, by modality
8.2.2.6.3.Asia-Pacific nuclear medicine market, for Rest of Asia-Pacific, by application
8.2.2.6.4.Asia-Pacific nuclear medicine market, for Rest of Asia-Pacific, by end user

8.2.3.Asia-Pacific market size and forecast, by type
8.2.4.Asia-Pacific market size and forecast, by modality
8.2.5.Asia-Pacific market size and forecast, by application
8.2.6.Asia-Pacific market size and forecast, by end user

CHAPTER 9:COMPANY PROFILES

9.1.Bracco S.P.A. (Bracco Imaging S.P.A.)

9.1.1.Company overview
9.1.2.Company snapshot
9.1.3.Operating business segments
9.1.4.Product portfolio
9.1.5.Key strategic moves and developments

9.2.Bwx Technologies, Inc. (Nordion, Inc.)

9.2.1.Company overview
9.2.2.Company snapshot
9.2.3.Operating business segments
9.2.4.Product portfolio
9.2.5.Business performance
9.2.6.Key strategic moves and developments

9.3.Cardinal Health, Inc.

9.3.1.Company overview
9.3.2.Company snapshot
9.3.3.Operating business segments
9.3.4.Product portfolio
9.3.5.Business performance

9.4.Danaher Corporation (GE Healthcare)

9.4.1.Company overview
9.4.2.Company snapshot
9.4.3.Operating business segments
9.4.4.Product portfolio
9.4.5.Business performance
9.4.6.Key strategic moves and developments

9.5.FUJIFILM Toyama Chemical Co., Ltd. (FUJIFILM Holdings Corporation)

9.5.1.Company overview
9.5.2.Company snapshot
9.5.3.Operating business segments
9.5.4.Product portfolio
9.5.5.Business performance

9.6.Ion Beam Applications (Ion Beam Applications, SA)

9.6.1.Company overview
9.6.2.Company snapshot
9.6.3.Operating business segments
9.6.4.Product portfolio
9.6.5.Business performance
9.6.6.Key strategic moves and developments

9.7.Lantheus Holdings, Inc. (Lantheus Medical Imaging, Inc.)

9.7.1.Company overview
9.7.2.Company snapshot
9.7.3.Operating business segments
9.7.4.Product portfolio
9.7.5.Business performance

9.8.Novartis AG (Advanced Accelerator Applications S.A.)

9.8.1.Company overview
9.8.2.Company snapshot
9.8.3.Operating business segments
9.8.4.Product portfolio
9.8.5.Business performance

9.9.Otsuka Holdings Co., Ltd. (ABX advanced biochemical compounds GmbH)

9.9.1.Company overview
9.9.2.Company snapshot
9.9.3.Operating business segments
9.9.4.Product portfolio
9.9.5.Business performance

9.10.Siemens Healthcare GmbH

9.10.1.Company overview
9.10.2.Company snapshot
9.10.3.Operating business segments
9.10.4.Product portfolio
9.10.5.Business performance

LIST OF TABLES

TABLE 01.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY TYPE, 2020–2028($MILLION)
TABLE 02.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY MODALITY, 2020–2028($MILLION)
TABLE 03.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY APPLICATION, 2020–2028($MILLION)
TABLE 04.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY END USER, 2020–2028($MILLION)
TABLE 05.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 2020–2028 ($MILLION)
TABLE 06.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR JAPAN, BY MODALITY, 2020–2028
TABLE 07.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR JAPAN, BY APPLICATION, 2020–2028
TABLE 08.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR JAPAN, BY END USER, 2020–2028
TABLE 09.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR CHINA, BY TYPE, 2020–2028
TABLE 10.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR CHINA, BY MODALITY, 2020–2028
TABLE 11.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR, CHINA, BY APPLICATION, 2020–2028
TABLE 12.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR CHINA, BY END USER, 2020–2028
TABLE 13.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR INDIA, BY TYPE, 2020–2028
TABLE 14.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR INDIA, BY MODALITY, 2020–2028
TABLE 15.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR, INDIA, BY APPLICATION, 2020–2028
TABLE 16.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR INDIA, BY END USER, 2020–2028
TABLE 17.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR SOUTH KOREA, BY TYPE, 2020–2028
TABLE 18.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR SOUTH KOREA, BY MODALITY, 2020–2028
TABLE 19.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR, SOUTH KOREA, BY APPLICATION, 2020–2028
TABLE 20.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR SOUTH KOREA, BY END USER, 2020–2028
TABLE 21.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR AUSTRALIA, BY TYPE, 2020–2028
TABLE 22.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR AUSTRALIA, BY MODALITY, 2020–2028
TABLE 23.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR, AUSTRALIA, BY APPLICATION, 2020–2028
TABLE 24.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR AUSTRALIA, BY END USER, 2020–2028
TABLE 25.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR REST OF ASIA-PACIFIC, BY TYPE, 2020–2028
TABLE 26.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR REST OF ASIA-PACIFIC, BY MODALITY, 2020–2028
TABLE 27.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR, REST OF ASIA-PACIFIC, BY APPLICATION, 2020–2028
TABLE 28.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR REST OF ASIA-PACIFIC, BY END USER, 2020–2028
TABLE 29.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY TYPE, 2020–2028
TABLE 30.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY MODALITY, 2020–2028
TABLE 31.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY APPLICATION, 2020–2028
TABLE 32.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY END USER, 2020–2028
TABLE 33.BRACCO S.P.A.: COMPANY SNAPSHOT
TABLE 34.BRACCO S.P.A.: OPERATING SEGMENTS
TABLE 35.BRACCO S.P.A.: PRODUCT PORTFOLIO
TABLE 36.BRACCO: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 37.BWXT: COMPANY SNAPSHOT
TABLE 38.BWXT: OPERATING SEGMENT
TABLE 39.BWXT: PRODUCT PORTFOLIO
TABLE 40.BWXT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 41.CARDINAL HEALTH: COMPANY SNAPSHOT
TABLE 42.CARDINAL HEALTH: OPERATING SEGMENT
TABLE 43.CARDINAL HEALTH: PRODUCT PORTFOLIO
TABLE 44.DANAHER: COMPANY SNAPSHOT
TABLE 45.DANAHER: OPERATING SEGMENT
TABLE 46.DANAHER: PRODUCT PORTFOLIO
TABLE 47.GE HEALTHCARE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 48.FUJIFILM: COMPANY SNAPSHOT
TABLE 49.FUJIFILM: OPERATING SEGMENT
TABLE 50.FUJIFILM: PRODUCT PORTFOLIO
TABLE 51.IBA: COMPANY SNAPSHOT
TABLE 52.IBA: OPERATING SEGMENT
TABLE 53.IBA: PRODUCT PORTFOLIO
TABLE 54.IBA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 55.LANTHEUS: COMPANY SNAPSHOT
TABLE 56.LANTHEUS: OPERATING SEGMENTS
TABLE 57.LANTHEUS: PRODUCT PORTFOLIO
TABLE 58.NOVARTIS: COMPANY SNAPSHOT
TABLE 59.NOVARTIS: OPERATING SEGMENTS
TABLE 60.NOVARTIS: PRODUCT PORTFOLIO
TABLE 61.OTSUKA: COMPANY SNAPSHOT
TABLE 62.OTSUKA: OPERATING SEGMENT
TABLE 63.OTSUKA: PRODUCT PORTFOLIO
TABLE 64.SIEMENS: COMPANY SNAPSHOT
TABLE 65.SIEMENS: OPERATING SEGMENTS
TABLE 66.SIEMENS: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.ASIA-PACIFIC NUCLEAR MEDICINES MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2017-2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2017-2021
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2017-2021
FIGURE 01.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 02.MODERATE BARGAINING POWER OF BUYERS
FIGURE 03.MODERATE THREAT OF SUBSTITUTES
FIGURE 04.MODERATE THREAT OF NEW ENTRANTS
FIGURE 05.MODERATE INTENSITY OF RIVALRY
FIGURE 06.TOP PLAYER POSITIONING, 2020
FIGURE 07.IMPACT ANALYSIS
FIGURE 08.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, DIAGNOSTICS, BY COUNTRY, 2020–2028 ($MILLION)
FIGURE 09.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, THERAPEUTICS, BY COUNTRY, 2020–2028 ($MILLION)
FIGURE 10.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BIOCHEMISTRY RESEARCH, BY COUNTRY, 2020–2028 ($MILLION)
FIGURE 11.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY SPECT, 2020–2028 ($MILLION)
FIGURE 12.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY PET, 2020–2028 ($MILLION)
FIGURE 13.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY BETA EMITTERS, 2020–2028 ($MILLION)
FIGURE 14.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY ALPHA EMITTERS, 2020–2028 ($MILLION)
FIGURE 15.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY BRACHYTHERAPY, 2020–2028 ($MILLION)
FIGURE 16.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY OTHERS, 2020–2028 ($MILLION)
FIGURE 17.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY ONCOLOGY, 2020–2028 ($MILLION)
FIGURE 18.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY CARDIOLOGY, 2020–2028 ($MILLION)
FIGURE 19.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY THYROID, 2020–2028 ($MILLION)
FIGURE 20.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY NEUROLOGY, 2020–2028 ($MILLION)
FIGURE 21.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY OTHERS, 2020–2028 ($MILLION)
FIGURE 22.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY HOSPITALS AND DIAGNOSTIC CENTERS, 2020–2028 ($MILLION)
FIGURE 23.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY RESEARCH INSTITUTES, 2020–2028 ($MILLION)
FIGURE 24.BWXT: NET SALES, 2018-2020($MILLION)
FIGURE 25.BWXT: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 26.BWXT: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 27.CARDINAL HEALTH: NET SALES, 2018-2020($MILLION)
FIGURE 28.CARDINAL HEALTH: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 29.CARDINAL HEALTH: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 30.DANAHER: NET SALES, 2018–2020 ($MILLION)
FIGURE 31.DANAHER: REVENUE SHARE BY SEGMENT, 2020
FIGURE 32.DANAHER: REVENUE SHARE BY REGION, 2020(%)
FIGURE 33.FUJIFILM: NET SALES, 2017-2019 ($MILLION)
FIGURE 34.FUJIFILM: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 35.IBA: NET SALES, 2018-2020($MILLION)
FIGURE 36.IBA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 37.LANTHEUS: NET SALES, 2018-2020($MILLION)
FIGURE 38.LANTHEUS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 39.NOVARTIS: NET SALES, 2018-2020($MILLION)
FIGURE 40.NOVARTIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 41.NOVARTIS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 42.OTSUKA: NET SALES, 2018-2020($MILLION)
FIGURE 43.OTSUKA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 44.SIEMENS: NET SALES, 2018-2020 ($MILLION)
FIGURE 45.SIEMENS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 46.SIEMENS: REVENUE SHARE BY REGION, 2020 (%)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[核医学のアジア太平洋市場2021年-2028年:種類別(診断、治療、生化学研究)、モダリティ別、用途別、エンドユーザー別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆